Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Oslo Bors  >  Gentian Diagnostics AS    GENT   NO0010748866


Real-time Quote. Real-time Oslo Bors - 04/09 10:25:02 am
59 NOK   -1.67%
04/08GENTIAN DIAGNOSTICS  : Cystatin C guided medication dosing
03/29NEWSLETTER : Clinical value of cystatin C #KidneyMonth
03/22AVAILABLE POSITIONS : Nordics and Europe
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gentian Diagnostics : Cystatin C guided medication dosing

04/08/2021 | 07:54am EDT
Assessment of kidney function for ensuring correct drug dosage

The kidneys are an important site of elimination for most medications and their metabolites. For this reason, an accurate assessment of kidney function is critical for ensuring correct dosage.

Chemotherapeutic agents and antibiotics are two classes of drugs for which an accurate understanding of a patient's renal function is particularly important. Whether they are conventional cytotoxic agents or molecularly targeted therapies, chemotherapy drugs are known to affect nephrons and renal microvasculature with clinical manifestations ranging from electrolyte disturbances and proteinuria to acute kidney injury (AKI) and progression of chronic kidney disease (CKD)1.

Similarly, high concentrations of antibiotics like vancomycinare associated with AKI and ototoxicity while concentrations below the therapeutic threshold could lead to treatment failure and a risk of developing bacterial resistance2,3.

eGFR and kidney function

Estimated Glomerular Filtration Rate (eGFR) (link) is the most commonly used parameter for assessing a patient's kidney function. The equations widely used to calculate eGFR consider a patient's plasma/serum concentration of creatinine along with demographic factors such as race, sex, and age4.

The primary issue with the majority of these formulas is that they were derived from studies that involved homogenous patient populations. For instance, the Cockcroft Gault equation cited in most package inserts provided by pharmaceutical manufacturers, was developed in 1976 based on creatinine clearance data from a population of 249 white males5.

Similarly, the Modification of Diet in Renal Disease (MDRD) study from which the MDRD formula was derived, only included patients with renal disease6. When the aforementioned is considered in combination with creatinine's dependence on muscle mass, it is easy to see why a growing body of research supports the clinical implementation of cystatin C-based dosing algorithms.

Cystatin C and creatinine in medication dosing protocols

The case for using cystatin C in addition to creatinine in medication dosing protocols is best made in a study published by the Mayo clinic, where a novel cystatin C and creatinine based vancomycin dosing algorithm (intervention) was compared to the standard approach (control) of calculating dose according to estimated creatinine clearance7.

Greater accuracy of antibiotic dosing

In this study, investigators found that 50 % of patients in the intervention arm of the study achieved a vancomycin dose within the therapeutic range compared to only 28 % in the control arm7. Additionally, patients who received the antibiotic according to the new algorithm achieved the desired dosage 25 % faster than patients following the standard approach7. This has broader implications for the level of care delivered at the institution because earlier identification of inadequate concentrations of the antibiotic would enable clinicians to either increase the dose or identify a more suitable therapeutic intervention7.

Co-reporting of cystatin C and creatine based eGFRs for adjustment of chemotherapy doses

A similar study published earlier this year (2021) by researchers at Marien hospital in Germany explored the benefits of adjusting cancer treatment doses according to a protocol that involved the co-reporting of cystatin C and creatine based eGFRs4. By providing personalised dosing regimens for those patients whose cystatin C-based eGFR differed from their creatinine-based eGFR by more than 15 ml/min/1.73m2, drug doses were lowered in 6.2 % of patients in the study population4.

Such a reduction is estimated to deliver 105,000per yearin savings from direct drug costs alone4. Given the 1800cost associated with performing cystatin C testing for the 606 patients in the study, the authors further pointed out that the benefit: Cost ratio of performing the test within the oncology unit would be 58:14. What is noteworthy here is that this cost-benefit analysis does not capture the value provided in-terms of increased physician confidence and increased patient satisfaction owing to side-effect avoidance.

Better outcomes at a lower cost

As the pace and pressure to embrace value-based care picks up globally, cystatin C could prove to be a valuable diagnostic tool for ensuring better patient outcomes at lower costs.

Contact Gentian

Want to know more about cystatin C and drug dosing or the Gentian Cystatin C Immunoassay? Send an email to marketing@gentian.com or fill out the form below:

  1. Santos, MLC et al. Nephrotoxicity in cancer treatment: An overview, in World J Clin Oncol, 2020. 11(4): p. 190-204.

  2. Frazee, EN et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study, in Crit Care, 2014. 18(3): p. R110.

  3. Begg, EJ, ML Barclay and CJ Kirkpatrick. The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999. 47(1): p. 23-30.

  4. Hoenle, A et al. Avoiding insufficient therapies and overdosing with co-reporting eGFRs (estimated glomerular filtration rate) for personalized drug therapy and improved outcomes - a simulation of the financial benefits. EJIFCC, 2021. 32(1): p. 41-51.

  5. Cockcroft, DW and MH Gault, Prediction of creatinine clearance from serum creatinine. Nephron, 1976. 16(1): p. 31-41.

  6. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.

  7. Frazee, E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. Am J Kidney Dis, 2017. 69(5): p. 658-666.

Webinar about drug dosing and cystatin C


Gentian Diagnostics AS published this content on 08 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 April 2021 11:53:07 UTC.

© Publicnow 2021
04/08GENTIAN DIAGNOSTICS  : Cystatin C guided medication dosing
03/29NEWSLETTER : Clinical value of cystatin C #KidneyMonth
03/22AVAILABLE POSITIONS : Nordics and Europe
03/18GENTIAN DIAGNOSTICS  : Shortcomings of the current standard of kidney care
03/11THE CYSTATIN C DIGEST : Feb 2021 Study Summary
03/08GENTIAN DIAGNOSTICS  : Cystatin C webinar series
03/04GENTIAN DIAGNOSTICS  : We are looking for a Business Development Manager based i..
02/24WEBINAR : Clinical value of cystatin C in drug dosing
02/18GENTIAN DIAGNOSTICS  : Publication of NT-proBNP patent application
02/18GENTIAN DIAGNOSTICS  : We are looking for a Nordic Sales Manager
More news
Sales 2020 78,5 M 9,25 M 9,25 M
Net income 2020 -14,0 M -1,65 M -1,65 M
Net cash 2020 151 M 17,8 M 17,8 M
P/E ratio 2020 -65,0x
Yield 2020 -
Capitalization 909 M 107 M 107 M
EV / Sales 2020 9,65x
EV / Sales 2021 9,59x
Nbr of Employees -
Free-Float 44,0%
Duration : Period :
Gentian Diagnostics AS Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus BUY
Number of Analysts 1
Average target price 81,00 NOK
Last Close Price 59,00 NOK
Spread / Highest target 37,3%
Spread / Average Target 37,3%
Spread / Lowest Target 37,3%
EPS Revisions
Managers and Directors
Hilja Ibert Chief Executive Officer
Njaal Kind Group Chief Financial Officer
Thomas Settevik Chairman
Erling M. H. Sundrehagen Chief Scientific Officer
Torsten Knüttel Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
10X GENOMICS, INC.37.46%21 168
BIOMÉRIEUX-3.60%15 642
NATERA, INC.5.49%9 089
DIASORIN S.P.A.-17.93%9 059